Molecular hydrogen is comparable to sulfasalazine as a treatment for DSS-induced colitis in mice.
Tyler W LeBaron, Fereshteh Asgharzadeh, Majid Khazei, Branislav Kura, Alex Tarnava, Jan Slezak · EXCLI journal · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, although sulfasalazine significantly reduced MDA levels compared to the colitis model (P < 0.001), H₂ with and without sulfasalazine was significantly more effective compared to sulfasalazine treatment (P < 0.001), and essentially prevented the DSS-induced MDA increase. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in mice. Although sulfasalazine significantly reduced MDA levels compared to the colitis model (P < 0.001), H₂ with and without sulfasalazine was significantly more effective compared to sulfasalazine treatment (P < 0.001), and essentially prevented the DSS-induced MDA increase.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 3.3 mL hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂; reported treatment duration: 7 days. Although sulfasalazine significantly reduced MDA levels compared to the colitis model (P < 0.001), H₂ with and without sulfasalazine was significantly more effective compared to sulfasalazine treatment (P < 0.001), and essentially prevented the DSS-induced MDA increase. The authors concluded that in another report, DSS was used to induce irritable bowel syndrome, which H₂ treatment also significantly attenuated (Shen et al., 2017[ 25 ]).
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The reported sample size was 6. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen exposure was 3.3 mL hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. The reported treatment duration was 7 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.